Global Raloxifene Hydrochloride Tablets Market Outlook 2022

Raloxifene Hydrochloride is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds.

The global Raloxifene Hydrochloride Tablets market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Raloxifene Hydrochloride Tablets volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Raloxifene Hydrochloride Tablets market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Raloxifene Hydrochloride Tablets Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Original Drugs
Generic Drugs

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Eli Lilly
Apotex Corporation
Teva Pharmaceutical
Jiangsu Hengrui Medicine
Aurobindo Pharma
Glenmark Pharmaceuticals
Sciegen Pharmaceuticals
Prasco Laboratories